官方服务：
资源简介：
Primary outcome(s): progression free survival
应用场景：
创建时间：
2022-11-15
相关数据集
PHASE II TRIAL OF FOLFIRI REGIMEN PLUS BEVACIZUMAB ALTERNATED WITH OXALIPLATIN-BASED HEPATIC ARTERIAL INFUSION PLUS DE GRAMONT REGIMEN AND BEVACIZUMAB IN THE TREATMENT OF UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER
Primary objectives: TUMOR RESPONSE RATE (RR)
NIAID Data Ecosystem50
Univariate and multivariate analysis for PFS in NK/T-cell lymphoma cases.
Univariate and multivariate analysis for PFS in NK/T-cell lymphoma cases.
NIAID Data Ecosystem40
Treatment of Childhood Nasopharyngeal Carcinoma With Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study
This phase III trial is studying how well radiation therapy, amifostine, and chemotherapy work in treating young patients with newly diagnosed nasopharyngeal cancer. Radiation therapy uses high-ener
DataCite Commons2025-06-01 更新40
Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy
To compare maintenance chemotherapy with Xeloda to control after best response with first line chemotherapy in advanced colorectal cancer. Main endpoint is progression free survival. A total of 300 pa
NIAID Data Ecosystem40
Second-line treatment of metastatic colorectal cancer with HR070803 in combination with 5-FU/LV and BP102
Interventions: experimental group:HR0708035, FU/LV and BP102 Primary outcome(s): Objective response rate Study Design: Single arm
NIAID Data Ecosystem40
